<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39291217</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>19</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2468-0249</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Kidney international reports</Title><ISOAbbreviation>Kidney Int Rep</ISOAbbreviation></Journal><ArticleTitle>Exploring Novel Adverse Events of Nefecon.</ArticleTitle><Pagination><StartPage>2705</StartPage><EndPage>2717</EndPage><MedlinePgn>2705-2717</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ekir.2024.07.006</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">Nefecon, the first innovative drug approved by both the US Food and Drug Administration (FDA) and European Medicines Agency for IgA nephropathy (IgAN), lacked comprehensive real-world assessments of its adverse events (AEs).</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We leveraged postmarketing data of Nefecon from the US FDA Adverse Event Reporting System (FAERS), employing disproportionate analysis (DPA) to detect positive signals at the system organ class (SOC) and preferred terms (PTs) levels. Duplicate AEs related to budesonide and those previously reported in studies were excluded through the use of the Medical Dictionary of Regulatory Activities (MedDRA). Our analysis encompassed time-to-onset (TTO), Weibull shape parameter (WSP) evaluation, cumulative incidence, clinical prioritization evaluation, and subgroup analysis based on gender and age.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">A total of 1515 individuals with IgAN were included. Five positive SOC signals and 23 positive PT signals were identified, including 4 PTs (asthenia, malaise, product dose omission issue, and anxiety) representing novel AEs newly identified in this study. None of the positive PTs were classified as high clinical priority, with only acne, hypertension, swelling face, and weight increased considered as moderate clinical priority events. The median time to TTO was 31 days. All WSP test results indicated an early failure type profile. Lastly, subgroup analysis provided further insights into the relative risk of specific AEs.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Nefecon demonstrates a favorable safety profile, with no high-priority clinical events identified. The identification of novel AEs and subgroup-specific relative high-risk events fills a gap in existing studies and offers valuable insights for early clinical vigilance.</AbstractText><CopyrightInformation>Â© 2024 International Society of Nephrology. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jingyu</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Renal Division, Peking University First Hospital, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Peking University Institute of Nephrology, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Chronic Kidney Disease Prevention and Treatment, Peking University, Ministry of Education, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Units of Diagnosis and Treatment of Immune-mediated Kidney Diseases, Chinese Academy of Medical Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Zhao</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Renal Division, Peking University First Hospital, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Peking University Institute of Nephrology, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Chronic Kidney Disease Prevention and Treatment, Peking University, Ministry of Education, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Units of Diagnosis and Treatment of Immune-mediated Kidney Diseases, Chinese Academy of Medical Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xingzi</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Renal Division, Peking University First Hospital, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Peking University Institute of Nephrology, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Chronic Kidney Disease Prevention and Treatment, Peking University, Ministry of Education, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Units of Diagnosis and Treatment of Immune-mediated Kidney Diseases, Chinese Academy of Medical Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Sufang</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Renal Division, Peking University First Hospital, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Peking University Institute of Nephrology, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Chronic Kidney Disease Prevention and Treatment, Peking University, Ministry of Education, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Units of Diagnosis and Treatment of Immune-mediated Kidney Diseases, Chinese Academy of Medical Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lv</LastName><ForeName>Jicheng</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Renal Division, Peking University First Hospital, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Peking University Institute of Nephrology, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Chronic Kidney Disease Prevention and Treatment, Peking University, Ministry of Education, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Units of Diagnosis and Treatment of Immune-mediated Kidney Diseases, Chinese Academy of Medical Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yuemiao</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Renal Division, Peking University First Hospital, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Peking University Institute of Nephrology, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Chronic Kidney Disease Prevention and Treatment, Peking University, Ministry of Education, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Units of Diagnosis and Treatment of Immune-mediated Kidney Diseases, Chinese Academy of Medical Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Hong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Renal Division, Peking University First Hospital, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Peking University Institute of Nephrology, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Chronic Kidney Disease Prevention and Treatment, Peking University, Ministry of Education, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Units of Diagnosis and Treatment of Immune-mediated Kidney Diseases, Chinese Academy of Medical Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>07</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Kidney Int Rep</MedlineTA><NlmUniqueID>101684752</NlmUniqueID><ISSNLinking>2468-0249</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">FAERS</Keyword><Keyword MajorTopicYN="N">IgA nephropathy</Keyword><Keyword MajorTopicYN="N">Nefecon</Keyword><Keyword MajorTopicYN="N">adverse events</Keyword><Keyword MajorTopicYN="N">budesonide</Keyword><Keyword MajorTopicYN="N">pharmacovigilance</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>6</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>18</Day><Hour>4</Hour><Minute>39</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>7</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39291217</ArticleId><ArticleId IdType="pmc">PMC11403076</ArticleId><ArticleId IdType="doi">10.1016/j.ekir.2024.07.006</ArticleId><ArticleId IdType="pii">S2468-0249(24)01822-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rodrigues J.C., Haas M., Reich H.N. IgA nephropathy. Clin J Am Soc Nephrol. 2017;12:677â686. doi: 10.2215/CJN.07420716.</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.07420716</ArticleId><ArticleId IdType="pmc">PMC5383386</ArticleId><ArticleId IdType="pubmed">28159829</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H., Barratt J. Is IgA nephropathy the same disease in different parts of the world? Semin Immunopathol. 2021;43:707â715. doi: 10.1007/s00281-021-00884-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00281-021-00884-7</ArticleId><ArticleId IdType="pubmed">34417628</ArticleId></ArticleIdList></Reference><Reference><Citation>Maixnerova D., El Mehdi D., Rizk D.V., Zhang H., Tesar V. New treatment strategies for IgA nephropathy: targeting plasma cells as the main source of pathogenic antibodies. JÂ Clin Med. 2022;11:2810. doi: 10.3390/jcm11102810.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11102810</ArticleId><ArticleId IdType="pmc">PMC9147021</ArticleId><ArticleId IdType="pubmed">35628935</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai K.N., Tang S.C.W., Schena F.P., et al. IgA nephropathy. Nat Rev Dis Primers. 2016;2:1â20. doi: 10.1038/nrdp.2016.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2016.1</ArticleId><ArticleId IdType="pubmed">27189177</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovin B.H., Adler S.G., Barratt J., et al. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100:S1âS276. doi: 10.1016/j.kint.2021.05.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2021.05.021</ArticleId><ArticleId IdType="pubmed">34556256</ArticleId></ArticleIdList></Reference><Reference><Citation>Tunnicliffe D.J., Reid S., Craig J.C., Samuels J.A., Molony D.A., Strippoli G.F. Non-immunosuppressive treatment for IgA nephropathy. Cochrane Database Syst Rev. 2024;2:CD003962. doi: 10.1002/14651858.CD003962.pub3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD003962.pub3</ArticleId><ArticleId IdType="pmc">PMC10832348</ArticleId><ArticleId IdType="pubmed">38299639</ArticleId></ArticleIdList></Reference><Reference><Citation>Bagchi S., Mani K., Swamy A., et al. Supportive management of IgA nephropathy with renin-angiotensin blockade, the AIIMS primary IgA nephropathy cohort (APPROACH) study. Kidney Int Rep. 2021;6:1661â1668. doi: 10.1016/j.ekir.2021.02.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ekir.2021.02.018</ArticleId><ArticleId IdType="pmc">PMC8207308</ArticleId><ArticleId IdType="pubmed">34169207</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y.M., Lv J.C., Wong M.G., Zhang H., Perkovic V. Glucocorticoids for IgA nephropathy-pro. Kidney Int. 2023;103:666â669. doi: 10.1016/j.kint.2023.01.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2023.01.018</ArticleId><ArticleId IdType="pubmed">36948768</ArticleId></ArticleIdList></Reference><Reference><Citation>Barratt J., Rovin B.H., Cattran D., et al. Why target the gut to treat IgA nephropathy? Kidney Int Rep. 2020;5:1620â1624. doi: 10.1016/j.ekir.2020.08.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ekir.2020.08.009</ArticleId><ArticleId IdType="pmc">PMC7569689</ArticleId><ArticleId IdType="pubmed">33102954</ArticleId></ArticleIdList></Reference><Reference><Citation>Stamellou E., Seikrit C., Tang S.C.W., et al. IgA nephropathy. Nat Rev Dis Primers. 2023;9:1â21. doi: 10.1038/s41572-023-00476-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41572-023-00476-9</ArticleId><ArticleId IdType="pubmed">38036542</ArticleId></ArticleIdList></Reference><Reference><Citation>Watts P., Smith A. TARGIT technology: coated starch capsules for site-specific drug delivery into the lower gastrointestinal tract. Expert Opin Drug Deliv. 2005;2:159â167. doi: 10.1517/17425247.2.1.159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/17425247.2.1.159</ArticleId><ArticleId IdType="pubmed">16296742</ArticleId></ArticleIdList></Reference><Reference><Citation>Smerud H.K., BÃ¡rÃ¡ny P., LindstrÃ¶m K., et al. New treatment for IgA nephropathy: enteric budesonide targeted to the ileocecal region ameliorates proteinuria. Nephrol Dial Transplant. 2011;26:3237â3242. doi: 10.1093/ndt/gfr052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfr052</ArticleId><ArticleId IdType="pubmed">21378156</ArticleId></ArticleIdList></Reference><Reference><Citation>FellstrÃ¶m B.C., Barratt J., Cook H., et al. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. Lancet. 2017;389:2117â2127. doi: 10.1016/S0140-6736(17)30550-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)30550-0</ArticleId><ArticleId IdType="pubmed">28363480</ArticleId></ArticleIdList></Reference><Reference><Citation>Barratt J., Lafayette R., Kristensen J., et al. Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. Kidney Int. 2023;103:391â402. doi: 10.1016/j.kint.2022.09.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2022.09.017</ArticleId><ArticleId IdType="pubmed">36270561</ArticleId></ArticleIdList></Reference><Reference><Citation>Lafayette R., Kristensen J., Stone A., et al. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial. Lancet. 2023;402:859â870. doi: 10.1016/S0140-6736(23)01554-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(23)01554-4</ArticleId><ArticleId IdType="pubmed">37591292</ArticleId></ArticleIdList></Reference><Reference><Citation>Barratt J., Lafayette R.A., Rovin B.H., FellstrÃ¶m B. Budesonide delayed-release capsules to reduce proteinuria in adults with primary immunoglobulin A nephropathy. Expert Rev Clin Immunol. 2023;19:699â710. doi: 10.1080/1744666X.2023.2206119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1744666X.2023.2206119</ArticleId><ArticleId IdType="pubmed">37103889</ArticleId></ArticleIdList></Reference><Reference><Citation>Yates M., Bechman K., Galloway J. The use of real-world data to address questions of patient safety. Rheumatology (Oxford) 2020;59:26â30. doi: 10.1093/rheumatology/kez158.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kez158</ArticleId><ArticleId IdType="pubmed">31834407</ArticleId></ArticleIdList></Reference><Reference><Citation>Knepper T.C., McLeod H.L. When will clinical trials finally reflect diversity? Nature. 2018;557:157â159. doi: 10.1038/d41586-018-05049-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-018-05049-5</ArticleId><ArticleId IdType="pubmed">29743700</ArticleId></ArticleIdList></Reference><Reference><Citation>Beaulieu-Jones B.K., Finlayson S.G., Yuan W., et al. Examining the use of real-world evidence in the regulatory process. Clin Pharmacol Ther. 2020;107:843â852. doi: 10.1002/cpt.1658.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpt.1658</ArticleId><ArticleId IdType="pmc">PMC7093234</ArticleId><ArticleId IdType="pubmed">31562770</ArticleId></ArticleIdList></Reference><Reference><Citation>Food and Drug Administration, HHS International conference on harmonisation; electronic transmission of postmarket individual case safety reports for drugs and biologics, excluding vaccines; availability of Food and Drug Administration regional implementation specifications for ICH E2B(R3) reporting to the Food and Drug Administration Adverse Event Reporting System. Notice of availability. Fed Regist. 2016;81:40890â40891.</Citation><ArticleIdList><ArticleId IdType="pubmed">27373012</ArticleId></ArticleIdList></Reference><Reference><Citation>Shu Y., Ding Y., Liu Y., Zhang Q., He X., Zhang Q. Post-marketing safety concerns with secukinumab: a disproportionality analysis of the FDA Adverse Event Reporting System. Front Pharmacol. 2022;13 doi: 10.3389/fphar.2022.862508.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.862508</ArticleId><ArticleId IdType="pmc">PMC9214234</ArticleId><ArticleId IdType="pubmed">35754494</ArticleId></ArticleIdList></Reference><Reference><Citation>Research C for de and  . FDA; 2021. FDA Adverse Event Reporting System (FAERS)https://www.fda.gov/drugs/drug-approvals-and-databases/fda-adverse-event-reporting-system-faers</Citation></Reference><Reference><Citation>FDA  FAERS quarterly data extract files. https://fis.fda.gov/extensions/FPD-QDE-FAERS/FPD-QDE-FAERS.html</Citation></Reference><Reference><Citation>Shimada K., Hasegawa S., Nakao S., et al. Adverse reaction profiles of hemorrhagic adverse reactions caused by direct oral anticoagulants analyzed using the Food and Drug Administration Adverse Event Reporting System (FAERS) database and the Japanese Adverse Drug Event Report (JADER) database. Int J Med Sci. 2019;16:1295â1303. doi: 10.7150/ijms.34629.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijms.34629</ArticleId><ArticleId IdType="pmc">PMC6775265</ArticleId><ArticleId IdType="pubmed">31588196</ArticleId></ArticleIdList></Reference><Reference><Citation>Noguchi Y., Tachi T., Teramachi H. Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source. Brief Bioinform. 2021;22:bbab347. doi: 10.1093/bib/bbab347.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bib/bbab347</ArticleId><ArticleId IdType="pubmed">34453158</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhai Y., Ye X., Hu F., et al. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system. JÂ Immunother Cancer. 2019;7:286. doi: 10.1186/s40425-019-0754-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40425-019-0754-2</ArticleId><ArticleId IdType="pmc">PMC6836403</ArticleId><ArticleId IdType="pubmed">31694698</ArticleId></ArticleIdList></Reference><Reference><Citation>Caster D.J., Lafayette R.A. The treatment of primary IgA nephropathy: Change, Change, Change. Am J Kidney Dis. 2024;83:229â240. doi: 10.1053/j.ajkd.2023.08.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2023.08.007</ArticleId><ArticleId IdType="pubmed">37742867</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA. Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=215935</Citation></Reference><Reference><Citation>Kinpeygo  European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/kinpeygo</Citation></Reference><Reference><Citation>Gatti M., Antonazzo I.C., Diemberger I., De Ponti F., Raschi E. Adverse events with sacubitril/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system. Eur J Prev Cardiol. 2021;28:983â989. doi: 10.1177/2047487320915663.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2047487320915663</ArticleId><ArticleId IdType="pubmed">34402868</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng Z., Liu J., Gong H., Cai X., Xiao H., Gao W. Psychiatric disorders associated with PCSK9 inhibitors: a real-world, pharmacovigilance study. CNS Neurosci Ther. 2024;30 doi: 10.1111/cns.14522.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cns.14522</ArticleId><ArticleId IdType="pmc">PMC11017405</ArticleId><ArticleId IdType="pubmed">37950531</ArticleId></ArticleIdList></Reference><Reference><Citation>EudraVigilance system overview  European Medicines Agency. https://www.ema.europa.eu/en/human-regulatory-overview/research-development/pharmacovigilance-research-development/eudravigilance/eudravigilance-system-overview</Citation></Reference><Reference><Citation>Signal management  European Medicines Agency. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/pharmacovigilance-post-authorisation/signal-management#designated-medical-events-10341</Citation></Reference><Reference><Citation>Kinoshita S., Hosomi K., Yokoyama S., Takada M. Time-to-onset analysis of amiodarone-associated thyroid dysfunction. JÂ Clin Pharm Ther. 2020;45:65â71. doi: 10.1111/jcpt.13024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcpt.13024</ArticleId><ArticleId IdType="pubmed">31400296</ArticleId></ArticleIdList></Reference><Reference><Citation>de Vries S.T., Denig P., Ekhart C., Mol P.G.M., van Puijenbroek E.P. Sex differences in adverse drug reactions of metformin: A longitudinal survey study. Drug Saf. 2020;43:489â495. doi: 10.1007/s40264-020-00913-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-020-00913-8</ArticleId><ArticleId IdType="pmc">PMC7165141</ArticleId><ArticleId IdType="pubmed">32048185</ArticleId></ArticleIdList></Reference><Reference><Citation>Noguchi Y., Yoshimura T. Detection algorithms for simple two-group comparisons using spontaneous reporting systems. Drug Saf. 2024;47:535â543. doi: 10.1007/s40264-024-01404-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-024-01404-w</ArticleId><ArticleId IdType="pubmed">38388828</ArticleId></ArticleIdList></Reference><Reference><Citation>European Medicines Agency  Screening for adverse reactions in EudraVigilance. https://www.ema.europa.eu/en/documents/other/screening-adverse-reactions-eudravigilance_en.pdf</Citation></Reference><Reference><Citation>Ray A. Beyond debacle and debate: developing solutions in drug safety. Nat Rev Drug Discov. 2009;8:775â779. doi: 10.1038/nrd2988.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd2988</ArticleId><ArticleId IdType="pubmed">19763107</ArticleId></ArticleIdList></Reference><Reference><Citation>Silberstein S.D., Reshef S., Cohen J.M., et al. Adverse events reported with therapies targeting the CGRP pathway during the first 6 months post-launch: a retrospective analysis using the FDA adverse events reporting system. Adv Ther. 2023;40:445â459. doi: 10.1007/s12325-022-02346-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12325-022-02346-4</ArticleId><ArticleId IdType="pmc">PMC9898337</ArticleId><ArticleId IdType="pubmed">36350532</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu X., Lin Z., Toney E., et al. Pharmacokinetics, tissue residue depletion, and withdrawal interval estimations of florfenicol in goats following repeated subcutaneous administrations. Food Chem Toxicol. 2023;181 doi: 10.1016/j.fct.2023.114098.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.fct.2023.114098</ArticleId><ArticleId IdType="pubmed">37838212</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Chen S., Wen Z., et al. Comparative pharmacokinetics of free doxorubicin and a liposomal formulation in cats following intravenous administration. Front Vet Sci. 2024;11 doi: 10.3389/fvets.2024.1353775.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fvets.2024.1353775</ArticleId><ArticleId IdType="pmc">PMC10827984</ArticleId><ArticleId IdType="pubmed">38298449</ArticleId></ArticleIdList></Reference><Reference><Citation>Nesbitt H., American Society of Nephrology  Kidney week - abstract details. https://www.asn-online.org/education/kidneyweek/2019/program-abstract.aspx?controlId=3236815</Citation></Reference><Reference><Citation>Bangsgaard R., Main K.M., Boberg-Ans G., et al. Adrenal suppression in infants treated with topical ocular glucocorticoids. Ophthalmology. 2018;125:1638â1643. doi: 10.1016/j.ophtha.2018.04.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2018.04.035</ArticleId><ArticleId IdType="pubmed">29934270</ArticleId></ArticleIdList></Reference><Reference><Citation>Afandi B., Toumeh M.S., Saadi H.F. Cushingâs syndrome caused by unsupervised use of ocular glucocorticoids. Endocr Pract. 2003;9:526â529. doi: 10.4158/EP.9.6.526.</Citation><ArticleIdList><ArticleId IdType="doi">10.4158/EP.9.6.526</ArticleId><ArticleId IdType="pubmed">14715481</ArticleId></ArticleIdList></Reference><Reference><Citation>Donaldson A.M., Choby G., Kim D.H., Marks L.A., Lal D. Intranasal corticosteroid therapy: systematic review and meta-analysis of reported safety and adverse effects in children. Otolaryngol Head Neck Surg. 2020;163:1087â1096. doi: 10.1177/0194599820931454.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0194599820931454</ArticleId><ArticleId IdType="pubmed">32660332</ArticleId></ArticleIdList></Reference><Reference><Citation>Pofi R., Caratti G., Ray D.W., Tomlinson J.W. Treating the side effects of exogenous glucocorticoids; can we separate the good from the bad? Endocr Rev. 2023;44:975â1011. doi: 10.1210/endrev/bnad016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/endrev/bnad016</ArticleId><ArticleId IdType="pmc">PMC10638606</ArticleId><ArticleId IdType="pubmed">37253115</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramjee L., Vurgun N., Ngai C., Patel M., Tremblay G. Cost-Effectiveness Analysis of Nefecon versus Best Supportive Care for People with Immunoglobulin A Nephropathy (IgAN) in the United States. Clinicoecon Outcomes Res. 2023;15:213â226. doi: 10.2147/CEOR.S389456.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CEOR.S389456</ArticleId><ArticleId IdType="pmc">PMC10067365</ArticleId><ArticleId IdType="pubmed">37020570</ArticleId></ArticleIdList></Reference><Reference><Citation>El Karoui K., Fervenza F.C., De Vriese A.S. Treatment of IgA nephropathy: a rapidly evolving field. JÂ Am Soc Nephrol. 2024;35:103â116. doi: 10.1681/ASN.0000000000000242.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.0000000000000242</ArticleId><ArticleId IdType="pmc">PMC10786616</ArticleId><ArticleId IdType="pubmed">37772889</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan J., Luo X., Yang J., et al. Clinicopathological characteristics and risk factors in elderly patients with biopsy-proven IgA nephropathy. Ren Fail. 2022;44:1027â1037. doi: 10.1080/0886022X.2022.2087527.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/0886022X.2022.2087527</ArticleId><ArticleId IdType="pmc">PMC9246206</ArticleId><ArticleId IdType="pubmed">35766236</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan Z.Y., Cai G.Y., Chen Y.Z., et al. Aging promotes progression of IgA nephropathy: a systematic review and meta-analysis. Am J Nephrol. 2013;38:241â252. doi: 10.1159/000354646.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000354646</ArticleId><ArticleId IdType="pubmed">24021632</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>